Angered by a controversial Allergan (AGN) patent maneuver, Sen. Claire McCaskill (D-Mo.) on Thursday introduced a bill that prohibits tribal sovereign immunity from being used to block certain types of patent challenges.

Her move comes after Allergan transferred six patents for its best-selling Restasis eye treatment last month to a Mohawk tribe, which has sovereign immunity and is now attempting to use its status to block patent challenges filed by several generic drug makers.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Changing the law is the only recourse. In 1998 the Supreme Court, in the case of the Kiowa tribe of Oklahoma vs Manufacturing Technologies, Inc. ruled that Sovereign Tribal Nations are immune from civil lawsuits.

Your daily dose of news in health and medicine

Privacy Policy